GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara ...
Objective: While others have shown adverse remodeling of BM ECs during atherogenesis, whether splenic ECs show a similar dysfunction leading to exacerbated hematopoiesis has not been described.
PALO ALTO, Calif.--(BUSINESS WIRE)--FidoCure, a leader in AI-driven precision oncology for dogs, is excited to share landmark findings on canine splenic hemangiosarcoma at the 2024 Veterinary ...